Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.54 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 4/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537002 | 0.93 | USP28 (0.60) | USP28USP25CCR5HTTPTGER1 | |
| SCHEMBL547302 | 0.88 | CCR5 (0.54) | USP28USP25CCR5HTTPTGES | |
| SCHEMBL10050013 | 0.86 | PTGER1 (0.48) | CCR5FFAR1FFAR4HTTPTGER1 | |
| SCHEMBL7823412 | 0.86 | PTGER1 (0.54) | FFAR1FFAR4PTGER1 | |
| SCHEMBL4767265 | 0.84 | USP28 (0.59) | USP28USP25CCR5HTTPTGER1 | |
| SCHEMBL4032841 | 0.81 | FFAR1 (0.61) | FFAR1 | |
| SCHEMBL2538737 | 0.81 | PTGER1 (0.61) | CCR5PTGER1RXRARXRBRAB9A | |
| SCHEMBL15820919 | 0.81 | CCR5 (0.60) | USP28USP25CCR5HTTPTGER1 | |
| SCHEMBL16294058 | 0.80 | PTGER1 (0.64) | USP28USP25CCR5FFAR1FFAR4 | |
| SCHEMBL21438534 | 0.80 | HSD17B10 (0.68) | PTGER1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110601-B2 | Compound, α1 adrenergic receptor antagonistic agent, and composition | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110601-B2 | Compound, α1 adrenergic receptor antagonistic agent, and composition | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | SUNTORY HOLDING LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | SUNTORY HOLDING LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128148-A1 | COMPOUND, ALPHA 1 ADRENALINE RECEPTOR ANTAGONIST, AND COMPOSITION | Suntory Holdings Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | ADRB1, ADRA1A, ADRA1D | USP28 4419/4885USP25 4280/4885CCR5 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.